Nine Square Therapeutics

Nine Square Therapeutics:

Name: Nine Square Therapeutics Slogan: A quest to alter the trajectory of neurodegenerative disease Description: Founded by life sciences venture capital firm ATP and renowned scientists at the University of California San Francisco (UCSF), Nine Square is uniting machine learning-enabled image-based cell profiling, chemistry and computational sciences to develop more effective drugs, faster. They are building a diversified portfolio of first-in class drug candidates for genetically validated targets on the autophagy/lysosomal pathway to overcoming the historical challenges of treating severe neurodegenerative diseases. Currently advancing multiple programs through preclinical development, with lead optimization efforts underway towards IND-enabling studies. Founded: 2020 Industries: Biotechnology Headquarter: United States Last Investment: $4.50M grant investment at 12 September 2023 Last Investment Investors: The Michael J. Fox Foundation for Parkinson's Research

Nine Square Therapeutics, founded in 2020, is a biotechnology startup based in the United States. They are focused on developing more effective drugs for severe neurodegenerative diseases by leveraging machine learning-enabled image-based cell profiling and genetic targets on the autophagy/lysosomal pathway. The company received a $4.50M grant investment from The Michael J. Fox Foundation for Parkinson's Research in September 2023. Their approach, integrating chemistry and computational sciences, shows potential to alter the trajectory of neurodegenerative diseases.